2014, Number 1
Rev Hematol Mex 2014; 15 (1)
Castleman’s Disease
Nolasco-De la Rosa AL, Mosiñoz-Montes R, Román-Guzmán E, Hernández-Quintero JM, Reyes-Miranda AL, Quero-Sandova Fl
Language: Spanish
References: 8
Page: 21-25
PDF size: 305.37 Kb.
ABSTRACT
Castleman’s disease, described in 1954, is a linfoproliferative, benign,
low-frequent disorder. There are two histologic kinds of this disorder:
hialinovascular type (90%) and plasmatic cell type, the latter can be
associated to fever, weight loss, dermic eruption, anemia and hipergammaglobulinemia;
the most common affected places are thorax,
stomach and neck; it can also develop (but less frequently) on pelvis and
pancreas. Its etiopathology is confusing and includes the interleukine 6
expression and the probable association with the 8-type human herpes
virus. The only curative treatment is the surgical excision. This paper
reports the case of a 55-year-old male patient with hyalinovascular
Castleman’s disease and thoracic localization.
REFERENCES
Aguiar RM, Acevedo AP, Staffieri R. Enfermedad de Castleman: Presentación de un caso clínico. Fundación Dr. JR Villavicencio 2005:57-59.
Camacho R, Millán F, Scher P, Castrillón C, Panzuto O. Enfermedad de Castleman. Presentación de un caso y revisión bibliográfica. Rev Cir Infantil 2008; 14:51-54.
O’ReillyPE Jr, Joshi VV, Holbrook CT, Weisenburger DD, et al. Multicentric Castleman’s disease in a child with prominent thymic involvement: A case report and brief review of the literature. Mod Pathol 1993;6:776-780.
Garcipérez VF, Vega J, Fernández H, Mogollón M, Porro R. Enfermedad de Castleman que infiltra grandes vasos y aurícula derecha. Rev Esp Cardiol 2012;65:669-675.
Castleman B, Towne VW. Case report of Massachusetts General Hospital case 40011. N Engl J Med 1954;250:26-35.
6 Bandera B, Ainsworth C, Shikle J, Rupard E, Roach M. Treatment of unicentric Castleman disease with neoadjuvant rituximab. Chest 2010;138:1239-1241.
Regal MA, Aljehani YM, Bousbait H. Primary mediastinal Castleman’s disease. Rare Tumors 2010;2:11-12.
Sobrevilla CP, Aviles SA, Cortés PD, Rivas VS. Características clínicopatológicas de la enfermedad de Castleman. Experiencia en el Instituto Nacional de Cancerología. Cir Ciruj 2009;77:187-192.
Full text